Today: 20 March 2026
Texas InstrumentsTexas Instruments stock slides 3.6% as chip rally cools; Jan. 27 earnings call in focus

Texas InstrumentsTexas Instruments stock slides 3.6% as chip rally cools; Jan. 27 earnings call in focus

NEW YORK, Jan 7, 2026, 15:30 ET — Regular session

  • Texas Instruments shares fall in afternoon trade, lagging a mixed chip group
  • Company set its fourth-quarter and full-year 2025 earnings call for Jan. 27
  • Traders are watching for clearer signs the analog-chip inventory reset is easing

Texas Instruments Incorporated shares were down 3.6% at $185.23 in late afternoon trading on Wednesday, after closing at $192.10 a day earlier. NXP Semiconductors fell 3.1%, while Microchip Technology slid 2.0% and Analog Devices and ON Semiconductor each dipped about 0.4%.

The pullback matters because Texas Instruments is widely watched as a bellwether for analog chips used in factory gear and cars, markets that have been stuck in an inventory unwind. Investors have been quick to trade the stock on small shifts in demand signals.

This week’s moves underline how thin the conviction still is. Traders want confirmation that orders are stabilizing and that pricing and factory loadings can improve without another round of customer cuts.

TI said it will webcast its fourth-quarter and full-year 2025 earnings conference call on Tuesday, Jan. 27, at 3:30 p.m. Central time. Chief executive Haviv Ilan and finance chief Rafael Lizardi will take questions, along with investor relations head Mike Beckman, the company said. Texas Instruments

Earlier this week, TI unveiled new automotive chips and tools aimed at advanced driver-assistance systems, including a high-performance computing system-on-a-chip, or SoC (a processor that combines key functions on one chip), and a new imaging radar chip. “The automotive industry is moving toward a future where driving doesn’t require hands on the wheel,” said Mark Ng, a director of automotive systems at TI. Texas Instruments

Sentiment across the analog group improved after Microchip raised its fiscal third-quarter net sales forecast to about $1.19 billion on strong bookings. “Our bookings activity was very strong in the December quarter despite a holiday filled quarter,” Microchip CEO Steve Sanghi said. Reuters

Barron’s reported on Tuesday that Texas Instruments rose 8.2% as Microchip’s update sparked a broader bid for analog and auto-exposed chip names, including NXP. Barron’s

The wider market has been leaning back into AI-linked megacaps, and the S&P 500 hit a record high on Wednesday, Reuters reported. Investors were also looking toward Friday’s U.S. payrolls report after mixed labor data. Reuters

But the recovery case can still wobble if customers keep stretching out the inventory correction. Microchip said its improvement was tied to progress in “inventory correction” across distributors and direct customers and to new designs moving into production. Microchip Technology Incorporated

For Texas Instruments, the next catalyst is Jan. 27, when it reports results and gives fresh guidance on industrial demand, auto orders and factory utilization. Traders are also bracing for Friday’s jobs data and Microchip’s Feb. 5 report as near-term tests for the broader chip cycle.

Stock Market Today

  • Diageo Shares Fall 22% in One Month Amid Valuation Debate
    March 20, 2026, 10:31 AM EDT. Diageo PLC (LSE:DGE) has seen a sharp 22% drop in its share price over the past month, continuing a 16% decline across three months, reflecting investor reassessment of its growth and risk outlook. The stock currently trades at £14.02, about 29% undervalued against a £19.81 fair value estimate based on forecasts including 2.7% annual revenue growth and earnings rising to $4.3 billion by 2028. However, Diageo's price-to-earnings (P/E) ratio stands at 17.3, slightly above industry peers but below the fair ratio of 24.1, suggesting mixed market sentiment. Risks include changing alcohol consumption trends and emerging market volatility from regulatory and taxation pressures. Investors face a nuanced outlook balancing downside risks with potential upside from margin improvements and steady sales growth.
Merck stock slips after Cidara tender offer; $9 billion R&D hit and HPV schedule shift in focus
Previous Story

Merck stock slips after Cidara tender offer; $9 billion R&D hit and HPV schedule shift in focus

Costco stock price forecast: Wall Street’s $1,000 call meets a holiday-sales test after the bell
Next Story

Costco stock price forecast: Wall Street’s $1,000 call meets a holiday-sales test after the bell

Go toTop